Journals / İnfeksiyon Dergisi / 2006 / Cilt: 20 - Sayı: 2

Determination of index values to prevent repetitions in blood donor screening assays by AxSYM

AxSYN ile yapılan kan bankası tarama testlerinde EIA tekrarlarını engelleyecek indeks değerlerinin belirlenmesi

Pages
117–120
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Samples with EIA indexes above these values may be accepted as repeatedly reactive and further EIA repetitions can be avoided before performing supplemental tests.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The microparticle-based enzyme-linked immunoassay (AxSYM; Abbott Laboratories) can simultaneously detect antibodies against Human Immunodeficiency Virus (anti-HIV), Hepatitis C Virus (anti-HCV) and Hepatitis B Virus surface antigen (HBsAg) which are widely used for screening of blood donors for HIV, HBV, HCV infections.
📊
Key Findings & Data:This study was planned to determine the EIA index value (s/co) that can differentiate the repeatedly reactive samples from false reactive ones in order to decrease the need for EIA repetitions.
💡
Conclusion & Impact:Samples with EIA indexes above these values may be accepted as repeatedly reactive and further EIA repetitions can be avoided before performing supplemental tests.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The microparticle-based enzyme-linked immunoassay (AxSYM; Abbott Laboratories) can simultaneously detect antibodies against Human Immunodeficiency Virus (anti-HIV), Hepatitis C Virus (anti-HCV) and Hepatitis B Virus surface antigen (HBsAg) which are widely used for screening of blood donors for HIV, HBV, HCV infections. Nevertheless, reactivity on a screening immunoassay may represent false reactivity, particularly in low-risk populations such as voluntary blood donors. Therefore, some supplemental tests such as immunoblot and/or nucleic acid determination assays are required for repeatedly reactive samples. This study was planned to determine the EIA index value (s/co) that can differentiate the repeatedly reactive samples from false reactive ones in order to decrease the need for EIA repetitions. Sera of 196 blood donors were tested for anti-HCV, anti-HIV and HBsAg in order to determine the EIA indexes of the repeatedly reactive samples. The threshold EIA indexes of three assays with highest sensitivity and specificity were determined by using receiver operating characteristics (ROC) analysis. These values were ? 2.28 for anti-HCV, ? 5.22 for HBsAg and ?2.78 for anti-HIV. Samples with EIA indexes above these values may be accepted as repeatedly reactive and further EIA repetitions can be avoided before performing supplemental tests.

Özet

Mikropartikül EIA prensibine göre çalışan Abbott-AxSYM, insan immun yetmezlik virüs antikoru (anti-HIV), Hepatit C virüsüne karşı antikor (anti-HCV) ve Hepatit B virüs yüzey antijenini (HBs Ag) saptayabilen bir test sistemidir. Bu testler kan vericilerinde sıklıkla tarama testi olarak kullanılmaktadır. Ancak kan vericileri gibi riskin düşük olduğu topluluklarda yalancı reaksiyonlar sık görülebilmektedir. Reaktif bir örneğin gerçek pozitifliğinin belirlenmesi için sonucun tekrarlanır olduğunun gösterilmesi ve sonrasında immunoblot ve/veya nükleik asit saptama testleri gibi destek testlerinin uygulanması gerekmektedir. Bu çalışma, kan vericilerinde EIA tekrarlarını azaltabilmek için, tekrarlanabilirliğin mutlak olduğu örneklerdeki ilk test EIA indeksinin (örnek/eşik değer (s/co)) belirlenmesi amacıyla planlanmıştır. Yüz doksan altı verici serumunda, anti-HCV, anti-HIV ve HBsAg için yalancı reaksiyonu, tekrarlayan reaktiflikten ayırmada en yüksek duyarlılık ve özgüllüğe sahip EIA indeks değeri "Receiver Operating Characteristic" (ROC) analizi ile belirlenmiştir. Bu değerler, anti-HCV için ? 2.28, anti-HIV için ?2.78 ve HBsAg için ? 5.22 olarak saptanmıştır. Sonuç olarak, belirlenen indeks değerleri ve üzerindeki sonuçlarda EIA tekrarı yapılmadan destek testlerine geçilebileceği düşünülmektedir.

🔖

Cite This Article

ÖZKÜTÜK, A., SAYINER, A. A., GÜZÜNLER, M., ABACIOĞLU, Y. H., ERGÖR, A. (2022). Determination of index values to prevent repetitions in blood donor screening assays by AxSYM. İnfeksiyon Dergisi, Cilt: 20 - Sayı: 2, 117–120. https://ajindex.com/articles/546436

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29-36
  2. Linnet K, Brandt E. Assessing diagnostic tests once an optimal cutoff point has been selected. Clin Chem 1986; 32: 1341-6
  3. Marshall DA, Kleinman SH, Wong JB, et al. Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States. Vox Sang 2004; 86: 28-40
  4. Moerman B, Moons V, Sommer H, Schmitt Y, Stetter M. Evaluation of sensitivity for wild type and mutant forms of hepatitis B surface antigen by four commercial HbsAg assays. Clin Lab 2004; 50: 159-62
  5. Alter MJ, Kuhnert WL, Finelli L. Centers for Disease Control and Prevention. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention. MMWR Recomm Rep 2003; 52 (RR-3): 1-15
  6. Metz CE. Roc methodology in radiology imaging. Invest Radiol 1986; 21: 720-33
  7. Lusted LB. Decision making studies in patient management. N Engl J Med 1971; 284: 416-24
  8. Linnet K. A review on the methodology for assessing diagnostic tests. Clin Chem 1988; 34 1379-86
  9. Swets J A. Measuring the accuracy of diagnostic systems. Sc/ence 1988; 240:1285-93
  10. Pawlotsky JM, Lonjon I, Hezode C, et al. What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories? Hepatology 1998; 27: 1700-2
  11. Schroter M, Schafer P, Zollner B, et al. Strategies for reliable diagnosis of hepatitis C infection: the need for a serological confirmatory assay. J Med Virol 2001; 64: 320-4
  12. Polywka S, Schroter M, Feucht HH, Zollner B, Laufs R. Relevance of reactivity in commercially available hepatitis C virus antibody assays. J Clin Microbiol 2001; 39: 1665-8
  13. Dufour DR, Talastas M, Fernandez MD, et al. Low-positive anti-hepatitis C virus enzyme immunoassay results: an important predictor of low likelihood of hepatitis C infection. Clin Chem 2003; 49: 479-86.